

1 **Title: Sexual dysfunction among Nigerian women living with HIV infection**

2 **Oliver Ezechi<sup>1,2</sup>□, Folahanmi Akinsolu<sup>1,2</sup>□, Tititola Gbajabiamila<sup>1</sup>□, Ifeoma Idigbe<sup>1&</sup>, Paschal**  
3 **Ezeobi<sup>1,2</sup>□, Adesola Musa<sup>1,2&</sup>, Agatha Wapmuk<sup>1</sup>□**

4

5 **<sup>1</sup>Center for Reproduction and Population Health Studies, Department of Clinical Sciences, Nigerian**  
6 **Institute of Medical Research, Yaba, Lagos State, Nigeria**

7 **<sup>2</sup>Department of Public Health, Faculty of Basic Medical and Health Sciences, Lead City University,**  
8 **Ibadan, Oyo State, Nigeria**

9 **\*Corresponding author**

10 E-mail: [folahanmi.tomiwa@gmail.com](mailto:folahanmi.tomiwa@gmail.com): [Akinsolu.folahanmi@lcu.edu.ng](mailto:Akinsolu.folahanmi@lcu.edu.ng)

11

12 □These authors contributed equally to this work.

13 &These authors also contributed equally to this work.

14

15

16

## 17 ABSTRACT

### 18 Introduction

19 Sexual dysfunction in women with HIV is a necessary but understudied aspect of HIV complications in women  
20 living with HIV. This study reports the prevalence, pattern, and risk factors for sexual dysfunction in women  
21 living with HIV in southwest Nigeria.

### 22 Methods

23 A validated Female Sexual Function Index was used to determine sexual dysfunction in a cross-sectional study  
24 design involving 2926 adult women living with HIV in a large, publicly funded tertiary HIV treatment centre  
25 in Lagos, Nigeria. A score of less than 26.5 indicated sexual dysfunction. Multivariate logistic regression  
26 analysis was performed to identify risk factors for sexual dysfunction.  $P < 0.05$  was considered statistically  
27 significant at a 95% confidence interval (CI).

### 28 Results

29 The prevalence of sexual dysfunction was 71.4%. The types of dysfunctions detected included disorder of  
30 desire (76.8%), sexual arousal (66.0%), orgasm (50.0%), pain (47.2%), lubrication (47.2%), and satisfaction  
31 (38.8%). Multivariate analysis showed that menopause (aOR: 2.0; 1.4 – 4.1), PHQ score of 10 and above  
32 (aOR: 2.3; 1.7 – 3.2), co-morbid medical conditions (aOR: 1.8; 1.4 – 2.7), use of protease inhibitor-based  
33 antiretroviral therapy (aOR: 1.3; 1.2 - 2.1) and non-disclosure of HIV status (aOR: 0.7; 0.6-0.8) were factors  
34 associated with sexual dysfunction.

### 35 Conclusions

36 Sexual dysfunction is common among Nigerian women living with HIV. Menopause, use of protease  
37 inhibitor-based regimens, PHQ score of at least 10, co-morbid medical condition, and non-disclosure of HIV  
38 status were associated with sexual dysfunction. National HIV programmes, in addition to incorporating  
39 screening and management of sexual dysfunction in the guidelines, should sensitise and train health workers  
40 on the detection and treatment of sexual dysfunction.

41  
42 Abstract word count: 257  
43

44 **Keywords:** Sexual dysfunction, female sexual dysfunction, Female Sexual Function Index, human  
45 immunodeficiency virus, antiretroviral therapy, protease inhibitor, Nigeria

## 48 Introduction

49 The introduction and increased access to antiretroviral therapy have changed human immunodeficiency virus  
50 (HIV) infection, a disease once considered a death sentence, to a chronic, manageable health condition. The  
51 widespread availability and use of potent combination antiretroviral therapy have dramatically reduced the  
52 morbidity and mortality of HIV infection globally and in sub-Saharan Africa.<sup>4</sup>

53 The marked improvement in the clinical outcome of HIV infection has prompted a paradigm shift in the  
54 measure of HIV treatment success from mortality to quality of life.<sup>5</sup> Quality of life is a multidimensional  
55 construct defined as a subjective evaluation of one's functioning and well-being. It is affected not only by  
56 individual lifestyle but also by social norms, cultural practices, and belief systems, so it varies among regions  
57 and population groups.<sup>6,7</sup>

58 Numerous studies in sub-Saharan Africa have examined the health-related quality of life in HIV-infected  
59 persons, with most studies emphasizing the physical, mental, and social aspects of quality of life while leaving  
60 out the sexual function component.<sup>7-21</sup> The few studies that addressed some aspect of sexual functioning were  
61 either limited by sample size or did not use a globally accepted and validated tool, such as Female Sexual  
62 Function Index questionnaire, in conducting their study.<sup>19-21</sup> Few studies focused on sexual dysfunction among  
63 HIV-positive women, even though a high prevalence of sexual dysfunction in persons living with HIV/AIDS  
64 has been reported.<sup>22-24</sup>

65 There are many reasons to expect an increase in sexual dysfunction in persons living with HIV infections,  
66 with psychological, endocrine, and neurologic factors being the most important.<sup>25-27</sup> However, proving a link  
67 between these factors and sexual dysfunction is difficult, as many of the conditions commonly seen within the  
68 HIV context, such as depression, peripheral neuropathy, and hypogonadism, are associated with sexual  
69 dysfunction in other settings also.<sup>25,26</sup> Furthermore, establishing associations with drugs or classes of drugs is  
70 difficult, as these agents often are used in combinations, and some of the drug-related toxicities persist even  
71 after replacement with another drug, leading to wrong attribution.<sup>25,28,29</sup>

72 Whereas several studies have evaluated sexual dysfunction in HIV-positive men,<sup>30</sup> but few studies have  
73 examined the sexual function of women living with HIV/AIDS.<sup>25</sup> In Nigeria, despite its high HIV burden, an  
74 extensive literature search has revealed only three studies reporting on sexual dysfunction among HIV-positive  
75 women,<sup>22-24</sup> despite several studies on sexual dysfunction among women with chronic diseases, pregnancy,  
76 infertility, diabetes mellitus, or hypertension.<sup>31-36</sup> This study was conducted to determine the prevalence,  
77 pattern, and risk factors of sexual dysfunction among HIV-positive women in Lagos, Southwest Nigeria.

## 80 **Methods**

### 81 **Study setting, design, sample size, and sampling**

82 This cross-sectional study was conducted between January 2019 and December 2020 at a large publicly funded  
83 tertiary comprehensive HIV treatment centre in a cosmopolitan city in southwestern Nigeria. The centre has  
84 cumulatively enrolled over 25,000 HIV-positive clients, 65% of whom are women. To participate in the study,  
85 the women had to be older than 18 years and proven HIV-positive for more than six months. The minimal  
86 sample size for the study was calculated with Raosoft online sample size calculator (  
87 [http://www.raosoft.com/sample\\_size.html](http://www.raosoft.com/sample_size.html)),<sup>38</sup> with a 99% CI, 2.5% margin of error, and assumed prevalence of  
88 sexual dysfunction among HIV positive to be 61.0%.<sup>21</sup> A total sample size of 2916 HIV-positive women was  
89 required, assuming a 30% non-response rate. A total of 3205 respondents randomly selected from the clinic  
90 attendance register were recruited for the study.

91 HIV-positive women attending the treatment centre were approached for the interview after selection from  
92 the lists of attendees, using a proportionate stratified sampling method. This method enabled the generalization  
93 of the study's findings to the women in the clinic. Each clinic's two-patient categories, drug refill; and 3-6  
94 monthly physician consults, were considered a homogenous population. These two categories were often in  
95 the ratio of 2:1 at each of the three clinic days a week. The daily list of clinic attendees was categorized into  
96 the two groups above, each serving as a frame. Respondents were then selected from the frames by simple  
97 random sampling, using the ratio of 2:1. Those who accepted to participate and signed an informed consent  
98 form were recruited.

### 100 **Study tools, data collection, and statistical analysis**

101 A self-administered structured data collection form consisting of three sections, (A) Demographic  
102 characteristics, (B) Patient Depression Question (PHQ), and (C) Female Sexual Function Index, were used to  
103 collect data for the study. Low-literate respondents were assisted in completing the forms by trained research  
104 assistants. The respondents' hospital numbers were written on each form to enable linkage to respondents'  
105 medical records. The demographic section of the form captured respondents' socioeconomic characteristics,  
106 medical and reproductive history, current and previous antiretroviral treatment, and recent laboratory results  
107 (CD4 cell count and viral load). The second section was the PHQ-9,<sup>39,40</sup> a 9-item self-report questionnaire in  
108 which participants rated their feelings during the previous two weeks. Each question is scored 0 to 3 (0 = not  
109 at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day), resulting in a 0 to 27. The nine  
110 items reflect the DSM-IV criteria for major depressive disorders. For this study, a score of 10 and above was  
111 considered depression. The last section is the Female Sexual Function Index (FSFI)<sup>41,42</sup>, a 19-item self-report  
112 instrument that scores six domains of sexual function in women in the previous four weeks. These domains  
113 include desire (two items, questions 1–2), arousal (four items, questions 3–6), lubrication (four items,  
114 questions 7–10), orgasm (three items, questions 11–13), satisfaction (three items, questions 14–16), and pain  
115 (three items, questions 17–19). The total FSFI score was determined by the sum of the six domains, with the  
116 minimum and maximum scores possibly varying from 2.0 to 36.0. A score greater than 26.5 denoted a low  
117 level of sexual dysfunction, and a score of 26.5 or less indicated sexual dysfunction. Likewise, scores on  
118 desire, arousal, lubrication, orgasm, satisfaction, and pain, which are  $\leq 3.6$  (score range, 1.2–6),  $\leq 3.9$  (score  
119 range, 0–6),  $\leq 3.6$  (score range, 0–6),  $\leq 3.6$  (score range, 0–6),  $\leq 3.6$  (score range, 0–6) and  $\leq 4.4$  (score range,  
120 0–6), respectively; all indicate sexual dysfunction related to subdimensions.<sup>32,41–43</sup> The FSFI has been  
121 validated on a clinically diagnosed sample of women with female sexual disorders.<sup>44</sup> In our setting,<sup>43</sup> however,  
122 because the study was in a specific population, the validity and reliability in the study population were  
123 confirmed with 100 HIV-positive women. A Cronbach's alpha score of 0.85 was obtained, indicating good  
124 reliability.

125 The study results were presented as means and percentages. The total FSFI scores were categorized into  
126 dichotomous variables (normal sexual function and sexual dysfunction) using a cut-off point of 26.5.<sup>42,43</sup>

127 Frequency distributions were generated, and univariate analysis using relevant statistics was performed to  
128 identify factors associated with sexual dysfunction. Multivariate logistic regression was used to identify  
129 independent risk factors for sexual dysfunction while controlling for potential confounders, including the  
130 severity of HIV disease measured by CD4 count and HIV viral load, time since HIV diagnosis, duration of  
131 antiretroviral drug use, PHQ-9 score of  $\geq 10$ , co-morbid state, education, employment status, marital status,  
132 age, and menopausal state. Variables were entered into the model if their P value on univariate analysis was  
133  $\leq 0.25$  or less. The variable with the strongest association in the univariate model was estimated first, followed  
134 by others in descending order. In the analysis, the comparison group consisted of those with an FSFI score of  
135  $> 26.5$  (no sexual dysfunction).  $P < 0.05$  was considered statistically significant. Odds Ratios (OR) and 95%  
136 Confidence Intervals (CI) for the OR were also calculated. All analyses were performed with SPSS statistical  
137 software package version 23.0 for Windows, SPSS Inc., Chicago, IL, USA.

### 138 ***Ethical considerations***

139 Ethical approval for the study was obtained from the Institutional Review Board of the Nigerian Institute of  
140 Medical Research, Lagos, Nigeria. Written informed consent was obtained from participants after the study  
141 objectives and methods were explained to the participants. The participants were assured of the confidentiality  
142 and anonymity of their data during and after the study. The women who declined to consent to participate in  
143 the study were provided their routine care but excluded from participation in the study.  
144  
145  
146

## 147 Results

148 3205 HIV-positive women were approached to participate in the study, of which 3009 (93.9%) accepted and  
149 were given the study forms or interviewed by research assistants. The study forms 2926 (91.3%) women in a  
150 stable monogamous and heterosexual relationship were completed and retrieved.

### 151 *Sociodemographic and HIV-related characteristics of the respondents*

152 The sociodemographic characteristics of the HIV-positive women in the study are shown in Table 1. Most of  
153 the women were less than 35 years of age (68.5%), married (53.1%), Christian (73.2%), working (59.5%),  
154 and from one of the three major Nigerian ethnic groups (75.8%). 78.5% had completed at least a secondary  
155 education. Four hundred and thirty-two (14.8%) HIV-positive women were postmenopausal.

156 HIV-related characteristics of the respondents are shown in Table 2, and the time elapsed since HIV diagnosis  
157 ranged from 6 to 204 months, with a median of  $102 \pm 41$  months. In most respondents (56.5%), HIV diagnosis  
158 had been made within 120 months. Most of the women had CD4 cell counts above 200 cells/mm<sup>3</sup> (73.6%),  
159 not detectable HIV viral load (62.3%), HIV positive partners (56.5%) and had disclosed their HIV status to  
160 their partner (66.3%). Of the 2926 respondents in the study, 2051 (70.1%) received a non-nucleoside reverse  
161 transcriptase inhibitor-based regimen, and 874 (21.9%) received a protease inhibitor-based regimen. The  
162 duration of antiretroviral therapy (ART) among the respondents ranged from 6 to 204 months, with a median  
163 of  $101 \pm 31$  months. Whereas (1743; 59.6%) of the respondents treated with ART have been receiving it for  
164 less than 96 months, the remaining 1182 (52.6%) had been on receiving ART for 95 months or more. At the  
165 time of the interview, 509 (20.2%) women had opportunistic infections, and 564 (21.9%) had one or more co-  
166 morbid medical conditions.

### 167 *Respondents' PHQ-9 total score*

168 The total score ranged from 0 – 25, with a mean of  $5.6 \pm 2.3$ . Most respondents had PHQ-9 scores of less than  
169 10 (85.3%), and the remaining respondents (14.7%) had PHQ-9 scores of 10 and above. Only twenty-five  
170 respondents (0.8%) had a total score of 20 and above.

### 171 *Sexual dysfunction among the respondents*

172 Of the 2926 women with complete questionnaires, 2089 had FSFI score  $\leq 26.6$  or a sexual dysfunction rate of  
173 71.4% (CI: 68.4 – 75.3). The distribution of respondents with sexual dysfunction in each of the six domains  
174 of sexual function is shown in Table 4. The percentage of sexual dysfunction in the domains ranged from  
175 38.8% in the satisfaction domain to 76.8% in the desire domain. At least half of the respondents had  
176 dysfunction in desire (76.8%), arousal (66.0%), and orgasm (50.0%) domains. The proportion of respondents  
177 with dysfunction in pain, lubrication, and satisfaction domain was 47.2%, 47.2%, and 38.8%, respectively.

### 178 *Risk factors for sexual dysfunction among the cohort*

179 Table 5 shows the relationship between the women's sociodemographic characteristics, co-morbid conditions,  
180 HIV characteristics, and sexual dysfunction. On univariate analysis, a significant association was found  
181 between women aged 35 years and above (cOR: 1.4; 1.0 - 1.8), marital status (cOR:0.5;0.4 – 0.7), PHQ Score  
182 of 10 and above (cOR: 2.5; 1.6 – 4.0), postmenopausal state (cOR: 2.5; 1.1 – 5.6), co-morbid medical condition  
183 (cOR: 1.8; 1.1 - 3.0) and SD. No statistically significant association was found between educational status  
184 (p=0.51), religion (p=0.47), employment status (p=0.31), and sexual dysfunction. The relationship between  
185 HIV-related factors and sexual dysfunction is summarized in Table 6. A statistically significant association  
186 was also found between HIV status disclosure (cOR:0.7; 0.6 – 0.97), use of protease inhibitor-based  
187 antiretroviral drug regimen (cOR: 1.6; 1.1 - 2.4), duration of antiretroviral therapy of less than 96 months  
188 (cOR:1.5; 1.1 – 2.1), the presence of opportunistic infection (cOR: 1.6(1.1 – 2.4) and sexual dysfunction. Time  
189 elapsed since HIV diagnosis (p=0.18), CD4 count (p=0.8), HIV viral load (p=0.1), and partners' positive HIV  
190 status (p=0.6) have no significant association with sexual dysfunction.

193 After adjustment for potential confounding variables of age, menopausal age, duration of HIV infection,  
194 antiretroviral drug regimen, HIV status disclosure, presence of opportunistic infection, PHQ score, and co-  
195 morbid medical conditions in the multivariate logistic regression model, sexual dysfunction in HIV-positive  
196 women had an independent statistically significant association with the postmenopausal state (aOR: 2.0; 1.4  
197 – 4.1), PHQ score of 10 and above (aOR: 2.3; 1.7 – 3.2), co-morbid medical conditions (aOR: 1.8; 1.4 – 2.7),  
198 use of protease-based regimen (aOR: 1.3; 1.2 - 2.1), and HIV status disclosure (aOR: 0.7; 0.6-0.8).  
199  
200

## Discussion

Whereas several studies reporting the prevalence and risk factors for sexual dysfunction in the general population and select medical conditions abound,<sup>40-43</sup> data on sexual dysfunction among HIV-positive women is limited.<sup>21</sup> In Nigeria, with the second largest HIV burden globally, the situation is more dire, as only three publications have reported on sexual dysfunction among HIV-positive women.<sup>23-25</sup> The three Nigerian studies were conducted in a predominantly Muslim population with a relatively small sample size, making the findings difficult to generalize. In this study, we determined the prevalence, pattern, and risk factors for sexual dysfunction using information obtained from a large population of HIV-positive women residing in a cosmopolitan city that reflected sociocultural diversity who had been receiving antiretroviral therapy for much longer. The larger sample size also made it possible to conduct subgroup analyses that are powered to make generalization easier. Information obtained in the study will assist in identifying HIV-positive women with sexual dysfunction within the country, within our subregion, and elsewhere to provide adequate care.

The sexual dysfunction rate of 71.4% in this study is within 61.0 – 89.2% reported in Nigerian studies.<sup>23-25</sup> It is, however, higher than the rates reported among HIV-positive women in India<sup>45</sup> and Europe.<sup>46,47</sup> Although female sexual dysfunction is a widespread health condition, controversy exists regarding the burden of female sexual dysfunction; vast differences are reported within and between countries. The differences may reflect medical and psychological factors, especially in socioeconomic; cultural; and ethnic differences; the definition used for each type of dysfunction; the type of study tool, the method of data collection; samples; and characteristics of populations studied.<sup>23-25, 45-49</sup> In addition, the observed higher prevalence in our setting and sub-Saharan Africa may be due to cultural differences in the settings or reluctance of women in the sub-Saharan region to talk openly about sex and seek solutions for their sexual concerns.<sup>21,23-25, 45-49</sup> The various explanations for the observed differences have also made generalization and comparison of studies challenging. This study used a validated and standardized tool and a specific population group to ensure generalization to our population group and context. This study confirmed that HIV infection is associated with high sexual dysfunction and thus deserves close attention.<sup>23-25, 45-49</sup>

As expected, the frequency of abnormality in specific sexual function domains is higher in the HIV-positive population studied than in the general population, but it is like the frequency reported in other studies among HIV-positive women.<sup>25,45-47,50</sup> Previous studies reported an association between HIV infection and poor quality of life resulting from physical, psychological, or emotional factors.<sup>6-10</sup> Medical conditions, including HIV infection, reduce the quality of life and thus impact sexual function.<sup>20,21</sup> Findings in this study support this assertion, as a co-morbid medical condition (aOR: 1.8; 1.1 - 3.0) and patients' health questionnaire scores of at least 10 (aOR: 2.3; 1.7 - 3.2) retained independent statistically significant association with sexual dysfunction after controlling for potential confounding variables. More than half of the respondents in this study had dysfunction in at least three specific sex domains: desire (76.8%), arousal (66.0%), and orgasm (50.0%). A large proportion also had dysfunction in the remaining three sexual function domains: pain (47.2%), lubrication (47.2%), and satisfaction (38.8%) domain. These findings are similar to previous studies conducted in Nigeria and other African countries among HIV-positive women, in which the most prevalent type of sexual dysfunction was in the domain of desire, whereas the least was in the domain of pain.<sup>21-25,50</sup> The above finding, however, is higher than the findings of studies among the general population, but the distribution of degrees of dysfunction in the various domains was like the findings in women living with HIV.<sup>30,51-55</sup> Across most studies, dysfunction in the desire domain was the commonest, and dysfunction in the pain domain was the least common, as found in this study. Castelo-Branco et al.,<sup>54</sup> in their study among healthy women living in Santiago de Chile, found desire disorder (38.0%) the most common, followed by arousal disorder (32.0%), pain disorder (33%), and orgasm disorder (25.0%). In a study by Kadri and colleagues<sup>55</sup> among women living in Morocco, desire disorder was reported by 18%, orgasm disorder by 12%, arousal



248 disorder by 8%, and pain disorder by 8%. The inference that can be made from the above is that while the  
249 severity of specific domain dysfunction may be worse in HIV-positive women, their distribution and pattern  
250 of occurrence are like those in HIV-positive and HIV-negative women.<sup>21,23-25, 54,55</sup>

251 The present study found that the postmenopausal state (aOR: 2.5), PHQ score of at least 10 (aOR: 2.5),  
252 opportunistic infection (aOR:1.4), co-morbid medical condition (aOR: 1.8), use of protease-based  
253 antiretroviral regimen (aOR: 1.3), and HIV status disclosure (aOR: 0.7) were independently associated with  
254 sexual dysfunction in women living with HIV infection. A menopausal state was also found as a risk factor  
255 for sexual dysfunction in other studies involving women with known HIV status and the general  
256 population.<sup>21,56,57</sup> It is possible that changes in blood hormonal levels with age in women account for their  
257 decline in sexual functioning in menopause. <sup>21,50,58</sup> These changes occur in all women, not only those HIV-  
258 positive. The presence of opportunistic infection and co-morbid medical conditions, such as hypertension and  
259 diabetes, were also identified as risk factors for sexual dysfunction among women in this study. A common  
260 opportunistic infection among the cohort in our clinic is tuberculosis.<sup>59</sup> Available literature has reported that  
261 active tuberculosis disrupts sexual function in male and female patients. Tuberculosis usually disturbs  
262 the mental and physical well-being of those infected. Its chronic nature, long isolation period, and  
263 enormous pill burden taken over a long period may lead to sexual dysfunction. Tuberculosis of the female  
264 genital tract is one of the leading causes of reproductive dysfunction as well.<sup>60</sup> Sexual dysfunction is  
265 frequently a challenge in patients with other medical diseases, such as hypertension and diabetes, and it may  
266 occur either as a side effect of medications or as a component of the dysmetabolic syndrome of high blood  
267 pressure. <sup>30,33</sup> Hypertension and diabetes are two common medical comorbidities in our environment  
268 among the HIV patient population,<sup>61</sup> and 61.0 - 88% of patients with these diseases have sexual  
269 dysfunction;<sup>21,25,33,62</sup> thus, it is not surprising that co-morbid conditions retained an independent  
270 statistical association with sexual dysfunction even after controlling for other possible confounders. This  
271 association was also found in other studies in our environment. <sup>21,30,33</sup> The use of antiretroviral therapy  
272 has been shown to ameliorate sexual dysfunction in several studies<sup>21</sup>; however, we could not access this  
273 variable in our study, as it is now unethical not to start HIV-positive patients on antiretroviral therapy;  
274 the studies that reported the association between sexual dysfunction and the use of antiretroviral therapy  
275 were conducted before the treat-all policy was instituted. In the present study, we could only assess if  
276 there is an association between the type of antiretroviral therapy regimen and sexual dysfunction; this  
277 study, like some other previous studies,<sup>63,64</sup> found that the use of protease inhibitors was an independent  
278 risk factor for sexual dysfunction in HIV- positive women. Schrooten et al., <sup>63</sup>, in their study in 10 European  
279 countries of HIV-positive patients receiving antiretroviral agents, found a decrease in sexual interest and  
280 potency among those receiving protease inhibitors compared with protease inhibitor-naive patients.

281 In this study, non-disclosure of HIV status was also an independent risk factor for sexual dysfunction. This  
282 finding is consistent with the findings of previous studies.<sup>21,23</sup> In women with HIV, sexual dysfunction is  
283 complex because of contextual sociocultural issues, financial challenges, depression, caregiving duties, and  
284 challenges of status disclosure.<sup>21-23,50,65</sup> These issues are most likely to affect sexual function. However, the  
285 most challenging is the fear of disclosure of HIV status (which is known to result in violence) and the  
286 associated guilt, especially if the partner is HIV-negative or of unknown status. It is, therefore, not surprising  
287 that non-disclosure was found to be a risk factor for sexual dysfunction. The guilt of infecting an HIV-negative  
288 partner or the fear of violence following disclosure has the potential to impact the sexual functioning of the  
289 women involved negatively.

## 292 **Strengths and limitations**

293 Our study has strengths: It was conducted in an HIV-endemic country with a large sample size using an  
294 internationally accepted and validated tool. The study was also conducted in a cosmopolitan city with  
295 sociocultural, religious, and economic diversity mimicking what is present nationally. However, the study also  
296 has limitations: its cross-sectional design did not allow for the assessment of the temporal association between  
297 sexual dysfunction and various factors studied. The study was conducted in a single city and clinic, though of  
298 more than 20 million population and over 20,000 patients; this makes it difficult to generalize to all women  
299 living with HIV in Nigeria. FSFI, the study tool, has been criticized for considering only penetrative sex as  
300 the single requirement for sexual well-being. Finally, about 10% of eligible patients who were approached  
301 declined to participate, failed to return the data collection form, or returned incompletely answered forms;  
302 although the rate was relatively low, it could still have affected the generalizability of the study results.

## 303 **Conclusions**

304 Sexual dysfunction is a significant public health challenge among HIV-positive women in Nigeria and sub-  
305 Saharan Africa, where HIV is endemic. The sexual dysfunction rate of 71.4% confirms that it is a significant  
306 challenge in our setting. Sexual dysfunction in the six domains ranged from 38.8% in the satisfaction domain  
307 to 76.8% in the desire domain. Six factors are significantly associated with sexual dysfunction: menopausal  
308 state, PHQ score of 10 and above, opportunistic infection, co-morbid medical condition, use of protease-based  
309 antiretroviral regimen, and non-disclosure of HIV status. There is a need to sensitize and train healthcare  
310 workers to assess for sexual challenges during routine programmatic consultations. The national HIV  
311 programs should, as a matter of urgency, include screening and treatment of sexual dysfunctions among HIV-  
312 positive women in the country's treatment guidelines.

## References

1. McGee C. The Continuing Impact of HIV/AIDS on Development in Africa: A Systematic Analysis Using the Political Systems and Contagious Disease Theories. In *Africa and Globalization 2020* (pp. 171-187). Palgrave Macmillan, Cham.
2. Giguère K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, Jahn A, Wanyeki I, Mbofana F, Bakiono F, Mahy M. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data. *The Lancet HIV*. 2021 May 1;8(5):e284-93.
3. Ukaegbu E, Alibekova R, Ali S, Crape B, Issanov A. Trends of HIV/AIDS knowledge and attitudes among Nigerian women between 2007 and 2017 using Multiple Indicator Cluster Survey data. *BMC Public Health*. 2022 Dec;22(1):1-2.
4. Mojola SA, Angotti N, Denardo D, Schatz E, Xavier Gómez Olivé F. The end of AIDS? HIV and the new landscape of illness in rural South Africa. *Global Public Health*. 2022 Jan 2;17(1):13-25.
5. Rintamaki L, Kosenko K, Hogan T, Scott AM, Dobmeier C, Tingue E, Peek D. The role of stigma management in HIV treatment adherence. *International journal of environmental research and public health*. 2019 Dec;16(24):5003.
6. Alexander G, Thomas RA. Health-Related Quality of Life in HIV-positive Women on Long-Term Antiretroviral Therapy—A Study from Bangalore, South India. *World Journal of AIDS*. 2022 Apr 11;12(2):97-110.
7. Rasoolinajad M, Abedinia N, Noorbala AA, Mohraz M, Badie BM, Hamad A, Sahebi L. Relationship among HIV-related stigma, mental health and quality of life for HIV-positive patients in Tehran. *AIDS and Behavior*. 2018 Dec;22(12):3773-82.
8. Karugaba G, Thupayagale-Tshweneagae G, Moleki MM, Mabikwa OV, Matshaba M. Determinants of health-related quality of life in young adults living with perinatally acquired HIV infection in Botswana. *Southern African Journal of HIV Medicine*. 2022 Apr 29;23(1):10.
9. Abebe Weldsilase Y, Likka MH, Wakayo T, Gerbaba M. Health-related quality of life and associated factors among women on antiretroviral therapy in health facilities of Jimma Town, Southwest Ethiopia. *Advances in Public Health*. 2018 Sep 16;2018.
10. Osei-Yeboah J, Owiredu WK, Norgbe GK, Lokpo SY, Obirikorang C, Alote Allotey E, Gameli Deku J, Akomanin Asiamah E, Manaphraim NY, Senyo Kwasi Nyamadi P, Yiadom Boakye E. Quality of life of people living with HIV/AIDS in the Ho Municipality, Ghana: a cross-sectional study. *AIDS research and treatment*. 2017 Oct 24;2017.
11. Alemayehu M, Wubshet M, Mesfin N, Tamiru A, Gebayehu A. Health-related quality of life of HIV infected adults with and without Visceral Leishmaniasis in Northwest Ethiopia. *Health and quality of life outcomes*. 2017 Dec;15(1):1-0.
12. Surur AS, Teni FS, Wale W, Ayalew Y, Tesfaye B. Health related quality of life of HIV/AIDS patients on highly active antiretroviral therapy at a university referral hospital in Ethiopia. *BMC health services research*. 2017 Dec;17(1):1-8.
13. Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lönnmark E, Long L, Rosen S. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. *Health and quality of life outcomes*. 2019 Dec;17(1):1-5.
14. Kimera E, Vindevogel S, De Maeyer J, Reynaert D, Engelen AM, Nuwaha F, Rubaihayo J, Bilsen J. Challenges and support for quality of life of youths living with HIV/AIDS in schools and larger community in East Africa: a systematic review. *Systematic Reviews*. 2019 Dec;8(1):1-8.

15. Oladeji BD, Taiwo B, Mosuro O, Fayemiwo SA, Abiona T, Fought AJ, Robertson K, Ogunniyi A, Adewole IF. Suicidal behavior and associations with quality of life among HIV-infected patients in Ibadan, Nigeria. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*. 2017 Jul;16(4):376-82.
16. Kanu NE, Tobin-West CI. Health-related quality of life of HIV patients with and without tuberculosis registered in a Tertiary Hospital in Port Harcourt, Nigeria. *HIV & AIDS Review. International Journal of HIV-Related Problems*. 2018 Jan 1;17(3):210-7.
17. Biambo AA, Adibe MO, Liman HM, Ukwe CV. Health-related quality of life of HIV-infected patients taking different antiretroviral regimens at a tertiary healthcare facility in northern Nigeria. *Tropical Journal of Pharmaceutical Research*. 2018 May 11;17(3):549-57.
18. Suleiman BA, Yahaya M, Olaniyan FA, Sule AG, Sufiyan MB. Determinants of health-related quality of life among human immunodeficiency virus positive (HIV-positive) patients at Ahmadu Bello University teaching hospital, Zaria, Nigeria-2015. *BMC Public Health*. 2020 Dec;20(1):1-9.
19. Onyekonwu CL, Onyeka TC, Brenda NC, Ijoma UN, Unaogu NN, Onwuekwe IO, Ugwumba F, Nwutobo CR, Nwachukwu CV. Chronic HIV infection and health related quality of life in resource poor settings- an assessment from South East Nigeria. *African Health Sciences*. 2020 Apr 20;20(1):102-13.
20. Mehta SD, Nordgren RK, Agingu W, Otieno F, Odongo W, Odhiambo F, Bailey RC. Sexual quality of life and association with HIV and sexually transmitted infections among a cohort of heterosexual couples in Kenya. *The journal of sexual medicine*. 2018 Oct 1;15(10):1446-55.
21. Huntingdon B, Muscat DM, de Wit J, Duracinsky M, Juraskova I. Factors associated with general sexual functioning and sexual satisfaction among people living with HIV: a systematic review. *The Journal of Sex Research*. 2020 Sep 1;57(7):824-35.
22. Bouhlel S, Derbel CH, Nakhli J, Bellazreg F, Meriem HB, Omezzine A, Ali BB. Sexual dysfunction in Tunisian patients living with HIV. *Sexologies*. 2017 Apr 1;26(2):e11-6.
23. Agaba PA, Meloni ST, Sule HM, Agaba EI, Idoko JA, Kanki PJ. Sexual dysfunction and its determinants among women infected with HIV. *International Journal of Gynecology & Obstetrics*. 2017 Jun;137(3):301-8.
24. Abiodun O, Sodeinde K, Adepoju A, Ohiaogu F, Mbonu F, Adelowo O, Bankole O. Sexual functioning, sexual distress, and well-being of sexually active adult women living with HIV: an HIV program-based cross-sectional study. *Sexuality Research and Social Policy*. 2020 Dec;17(4):558-67.
25. Oyedokun, A., Odeigah, L., Alabi, K., Adegunloye, O., Akujobi, H. (2014) Sexual dysfunction in HIV-positive women attending a tertiary health facility in North Central Nigeria. *J AIDS Clin Res*, 5: 398-398
26. Wilson TE, Jean-Louis G, Schwartz R, Golub ET, Cohen MH, Maki P, Greenblatt R, Massad LS, Robison E, Goparaju L, Lindau S. HIV infection and women's sexual functioning. *J Acquir Immune Defic Syndr*. 2010 Aug;54(4):360-7. doi: 10.1097/QAI.0b013e3181d01b14. PMID:
27. Shindel AW, Horberg MA, Smith JF, Breyer BN. Sexual dysfunction, HIV, and AIDS in men who have sex with men. *AIDS Patient Care STDS*. 2011 Jun;25(6):341-9. doi: 10.1089/apc.2011.0059. Epub 2011 Apr 18. PMID: 21501095; PMCID: PMC3101920.
28. Russell DB. Sexual function and dysfunction in older HIV-positive individuals. *Sex Health*. 2011 Dec;8(4):502-7. doi: 10.1071/SH11041. PMID: 22127035.
29. Scanavino Mde T. Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management. *Adv Urol*. 2011;2011:854792. doi: 10.1155/2011/854792. Epub 2011 Oct 20. PMID: 22046183; PMCID: PMC3199204.
30. Collazos J, Martínez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2002 Nov 1;31(3):322-6. doi: 10.1097/00126334-200211010-00008. PMID: 12439208.

31. De Vincentis S, Tartaro G, Rochira V, Santi D. HIV and Sexual Dysfunction in Men. *J Clin Med*. 2021 Mar 5;10(5):1088. doi: 10.3390/jcm10051088. PMID: 33807833; PMCID: PMC7961513.
32. Fajewonyomi BA, Orji EO, Adeyemo AO. Sexual dysfunction among female patients of reproductive age in a hospital setting in Nigeria. *Journal of Health, Population and Nutrition*. 2007 Mar 1:101-6.
33. Shaer KZ, Osegbe DN, Siddiqui SH, Razzaque A, Glasser DB, Jaguste V. Prevalence of erectile dysfunction and its correlates among men attending primary care clinics in three countries: Pakistan, Egypt, and Nigeria. *International journal of impotence research*. 2003 Apr 1;15:S8-14.
34. Okeahialam BN, Obeka NC. Sexual dysfunction in female hypertensives. *Journal of the National Medical Association*. 2006 Apr;98(4):638.
35. Audu BM. Sexual dysfunction among infertile Nigerian women. *Journal of Obstetrics and Gynaecology*. 2002 Jan 1;22(6):655-7.
36. Orji EO, Ogunlola IO, Fasubaa OB. Sexuality among pregnant women in South West Nigeria. *J Obstet Gynaecol*. 2002;22:166-8.
37. Adeniyi FA, Adeleye OJ, Adeniyi YC. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. *Current diabetes reviews*. 2010 Jul 1;6(4):201-6.
38. Raosoft Incorporated. Raosoft Sample size calculator 2004. Available from URL:<http://www.raosoft.com/samplesize.html>.
39. Kroenke, K., Spitzer, R.L., Williams, J.B., 2001. The PHQ-9. Validity of a brief depression severity measure. *J. Gen. Intern. Med*. 16, 606–613.
40. Adewuya AO, Ola BA, Afolabi OO. Validity of the Patient Health Questionnaire (PHQ-9) as a screening tool for depression amongst Nigerian university students. *Journal of Affective Disorders* 2006; 96: 9–93
41. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D'Agostino R. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *Journal of Sex & Marital Therapy*. 2000;26(2):191-208.
42. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cut-off scores. *J Sex Marital Ther*. 2005 Jan-Feb;31(1):1-20. doi: 10.1080/00926230590475206. PMID: 15841702.
43. Nwagha UI, Oguanuo TC, Ekwuazi K, Olubobokun TO, Nwagha TU, Onyebuchi AK, Ezeonu PO, Nwadike K. Prevalence of sexual dysfunction among females in a university community in Enugu, Nigeria. *Nigerian journal of clinical practice*. 2014;17(6):791-6.
44. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. *J Sex Marital Ther*. 2003 Jan-Feb;29(1):39-46. doi: 10.1080/713847100. PMID: 12519665; PMCID: PMC2872178.
45. Muthiah B, Kallikadavil A, Shivaswamy R, Menon VB. The Study of Gonadal Hormonal Abnormalities and Sexual Dysfunction in HIV Positive Females: An Exploratory Study. *Journal of Clinical and Diagnostic Research : JCDR*. 2016;10(4):OC11-OC14. doi:10.7860/JCDR/2016/18992.7581.
46. Goggin K, Engelson ES, Rabkin JG, Kotler DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. *Psychosom Med* 1998, 60:11-16
47. Florence E, Schrooten W, Dreezen C, Gordillo V, Schönnesson LN, Asboe D, Koitz G, Colebunders R, Eurosupport Study Group T. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. *AIDS care*. 2004 Jul 1;16(5):550-7.

- 446 48. Mezones-Holguin E, Cordova-Marcelo W, Lau-Chu-Fon F, Aguilar-Silva C, Morales-Cabrera J,  
447 Bolanos-Diaz R, et al. Association between sexual function and depression in sexually active, mid-aged,  
448 Peruvian women. *Climacteric* 2011;14:654-60.
- 449 49. Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: prevalence and associated  
450 risk factors. *International Journal of Impotence Research*. 2006 Jul 1;18(4):382-95.
- 451 50. Camara A, Tounkara TM, Delamou A, Baldé R, Leno NN, Kuotu GC, Touré A, Cissé M. Prevalence  
452 and risk factors of female sexual dysfunction among women infected with HIV in conakry. *Clinical  
453 Epidemiology and Global Health*. 2021 Oct 1;12:100828.
- 454 51. Turan V, Kopuz A, Ozcan A, Kocakaya B, Sahin C, Solmaz U. Sexual dysfunction in infertile Turkish  
455 females: prevalence and risk factors. *European Journal of Obstetrics & Gynecology and Reproductive  
456 Biology*. 2014;30;182:128-31.
- 457 52. Aygin D & Eti Aslan F (2008) A study of sexual dysfunction in women with breast cancer. *The Journal  
458 of Breast Health* 4, 105–114.
- 459 53. Cayan S, Akbay E, Bozlu M, Canpolat B, Acar D, Ulusoy E. The prevalence of female sexual dysfunction  
460 and potential risk factors that may impair sexual function in Turkish women. *Urologia Internationalis*  
461 2004;72, 52–57.
- 462 54. Castelo-Branco C, Blumel JE, Araya H, Riquelme R, Castro G, Haya J et al. Prevalence of sexual  
463 dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement  
464 therapy. *J Obstet Gynaecol* 2003; 23: 426–430.
- 465 55. Kadri N, Mchichi Alami KH, Mchakra Tahiri S. Women sexual dysfunction: a population-based  
466 epidemiological study. *Arch Women Ment Health* 2002; 5: 59–63.
- 467 56. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a  
468 primary care setting: a survey finding. *The journal of sexual medicine*. 2010 Sep 1;7(9):3080-7.
- 469 57. Hassanin IM, Helmy YA, Fathalla MM, Shahin AY. Prevalence and characteristics of female sexual  
470 dysfunction in a sample of women from Upper Egypt. *International Journal of Gynecology & Obstetrics*.  
471 2010 Mar 1;108(3):219-23.
- 472 58. Bernhard LA. Sexuality and sexual health care for women. *Clinical Obstetrics and gynecology*. 2002  
473 Dec 1;45(4):1089-98.
- 474 59. Onwujekwe DI, Ezechi OC, Ezeobi PM, Gbajabiamila TA. Incidence And Pattern Of Tuberculosis In HIV  
475 Infected Adult In Lagos Nigeria. *NJCBR Online*. 2017;7(9):23-8.
- 476 60. Kulchavenya E, Khomyakov V. Tuberculosis as a reason for male and female sexual dysfunction. Version:  
477 2018-10-04. In: Bjerklund Johansen TE, Wagenlehner FME, Matsumoto T, Cho YH, Krieger JN, Shoskes  
478 D, Naber KG, editors. *Urogenital Infections and Inflammations*. Berlin: German Medical Science GMS  
479 Publishing House; 2017-  
480 DOI: [10.5680/lhiii000041](https://doi.org/10.5680/lhiii000041)
- 481 61. Iwelunmor J, Ezechi O, Obiezu-Umeh C, Gbajabiamila T, Musa AZ, Oladele D, Idigbe I, Ohihoin A,  
482 Gyamfi J, Aifah A, Salako B. Capabilities, opportunities and motivations for integrating evidence-based  
483 strategy for hypertension control into HIV clinics in Southwest Nigeria. *PloS one*. 2019 Jun  
484 6;14(6):e0217703.
- 485 62. Ogberra AO, Chinenye S, Akinlade A, Eregie A, Awobusuyi J. Frequency and correlates of sexual  
486 dysfunction in women with diabetes mellitus. *The journal of sexual medicine*. 2009 Dec 1;6(12):3401-6.
- 487 63. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, Finazzi R, de Mey I, Florence  
488 E, Dreezen C, Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing  
489 highly active antiretroviral treatment, *AIDS*: May 25, 2001 - Volume 15 - Issue 8 - p 1019-1023

- 490 64. Martinez E, Collazos J, Mayo J. Sexual dysfunction with protease inhibitors. *Lancet* 1999, 353: 810 –  
491 811.
- 492 65. Goldmeier D, Kocsis A, Wasserman M. Sexual dysfunction in women with HIV. *Sexually Transmitted*  
493 *Infections*. 2005 Aug 1;81(4):284-.
- 494

495

**Table 1. Sociodemographic characteristics of 2926 HIV-positive women in the study**

<b>Characteristics</b>	<b>No. of Respondents (%)</b>
<b>Age (Years)</b>	
• < 35	2007(68.6)
• ≥ 35	919(31.4)
<b>Nigerian ethnic Groups</b>	
• Major ethnic groups (Igbo, H/Fulani, and Yoruba)	2218(75.8)
• Ethnic minorities	708(24.2)
<b>Education</b>	
• < Secondary	629(21.5)
• ≥ Secondary	2296(78.5)
<b>Employment status</b>	
• Working	1741(59.5)
• Not working	1185(40.5)
<b>Marital status</b>	
• Married	1553(53.1)
• Not married	1372(46.9)
<b>Religion</b>	
• Christianity	2142(73.2)
• Islam	711(24.9)
• Others	73(2.5)
<b>Menopausal state</b>	
• Premenopausal	2494(85.2)
• Postmenopausal	432(14.8)

496

497



498

**Table 2. HIV-related characteristics of the 2926 respondents in the study**

Characteristics	Frequency (%)
<b>Time since HIV diagnosis (months)</b>	
• < 120	1653(56.5)
• ≥ 120	1273(43.5)
<b>CD4 counts (2867)</b>	
• < 200	757(26.4)
• ≥ 200	2110(73.6)
• Median (SD)	563 (194)
<b>Viral load (2519)</b>	
• Not detected	1569(62.3)
• Detected	950(37.7)
<b>Partner HIV status (2448)</b>	
• Negative	1065(43.5)
• Positive	1383(56.5)
<b>HIV status Disclosure (2725)</b>	
• Disclosed	1807(66.3)
• Not disclosed	918(33.4)
<b>Type of antiretroviral therapy regimen</b>	
• NNRTI based	2051(70.1)
• PI based	874(29.9)
<b>Duration on ART (months)</b>	
• < 96	1743(59.6)
• ≥ 96	1182(40.4)
• Median (SD)	101(31)
<b>Opportunistic infection (2525)</b>	
• Yes	509(20.2)
• No	2016(79.8)
<b>Co-morbid medical condition (2575)</b>	
• Yes	564(21.9)
• No	2011(78.1)

499

500

501

**Table 3: Distribution of 2926 respondents PHQ-9 total score**

<b>Total score</b>	<b>Number of Respondents (%)</b>
<b>5 – 9</b>	2495(85.3)
<b>10 – 14</b>	313(10.7)
<b>15 – 19</b>	93(3.2)
<b>≥ 20</b>	25(0.8)
<b>Range</b>	0 – 25
<b>Mean (SD)</b>	5.6 (2.3)

502

503

**Table 4. Distribution of domain-specific sexual dysfunction among the 2926 respondents in the study**

<b>Sexual Domains</b>	<b>Number of respondents with sexual dysfunction (%)</b>
<b>Desire</b>	2247 (76.8)
<b>Arousal</b>	1931 (66.0)
<b>Lubrication</b>	1381 (47.2)
<b>Orgasm</b>	1463 (50.0)
<b>Satisfaction</b>	1135 (38.8)
<b>Pain</b>	1381 (47.2)

**Table 5. Relationship between sociodemographic variables and sexual dysfunction among 2926 HIV-positive women in the study**

**Table 6. Relationship between HIV-related variables and sexual dysfunction among 2926 HIV-positive women in the study**

Variables	Sexual dysfunction N= 2089	Normal sexual function N=837	Crude Odds Ratio (95% CI)	P value	Adjusted Odds Ratio (95% CI)	P value
<b>Age(years)</b>						
• <35	1393(69.4)	614(30.6)	1.0		1.0	
• ≥ 35	696(75.7)	223(24.3.)	<b>1.4(1.0 - 1.8)</b>	0.04	1.1(0.8-1.5)	0.09
<b>Education</b>						
• < Secondary	447(71.1)	182(28.9)	0.9(0.7-1.14)	0.51	-	-
• ≥ Secondary	1642(71.4)	655(28.6)	1.0		-	
<b>Employment status</b>						
• Working	1253(72.0)	488(28.0)	1.1(0.8-1.4)	0.31	-	-
• Not working	836(70.5)	349(29.5)	1.0		-	
<b>Marital status</b>						
• Married	1062(68.4)	491(31.6)	<b>0.5(0.4-0.7)</b>	0.00	<b>0.9(0.6-1.1)</b>	0.05
• Not married	1027(74.8)	346(25.2)	1.0		1.0	
<b>Religion</b>						
• <b>Christianity</b>	1525(71.2)	617(28.8)	1.0(0.7-1.3)	0.47	-	-
• <b>Islam</b>	504(70.9)	207(29.1)	1.0		-	
<b>PHQ Score</b>						
• <10	1723(69.1)	772(30.9)	1.0		1.0	
• ≥10	366(84.9)	65(15.1)	<b>2.5(1.6 – 4.0)</b>	<b>0.000</b>	<b>2.3(1.7 - 3.2)</b>	<b>0.000</b>
<b>Postmenopausal status</b>	370(85.7)	62(14.3)	<b>2.5(1.1 – 5.6)</b>	<b>0.013</b>	<b>2.0(1.4-4.1)</b>	<b>0.02</b>
<b>Co-morbid medical disorders</b>	456(80.8)	108(19.2)	<b>1.8(1.1 - 3.0)</b>	<b>0.02</b>	<b>1.8(1.4-2.7)</b>	<b>0.001</b>
<b>HIV Variables</b>	<b>Sexual dysfunction N=2089</b>	<b>Normal sexual function N=837</b>	<b>Crude OR (95% CI)</b>	<b>P value</b>	<b>Adjusted OR (95% CI)</b>	<b>P value</b>
<b>Time since HIV diagnosis (months)</b>						
• < 120	1160(70.2)	493(29.8)	0.9(0.7-1.1)	0.18	-	-

• $\geq 120$	929(72.9)	344(27.1)	1.0		-	
<b>CD4 count</b>						
• $<200$	560(74.0)	197(26.0)	1.8(0.6 – 3.1)	0.81	-	-
• $\geq 200$	1529(72.5)	581(27.5)	1.0		-	
<b>Viral load</b>						
• Not detected	1092(69.6)	477(30.4)	0.8(0.6 – 1.0)	0.1	-	-
• Detected	590(62.1)	360(37.9)	1.0		-	
<b>Partner HIV status</b>						
• <b>Positive</b>	1001(72.4)	383(27.6)	1.1(0.8 - 1.5)	0.60	-	-
• <b>Negative</b>	753(70.7)	312(29.4)	1.0		-	
<b>HIV status disclosure</b>						
• <b>Disclosed</b>	1250(69.2)	557(30.8)	<b>0.7(0.6 - 0.97)</b>	<b>0.04</b>	<b>0.7(0.6-0.8)</b>	<b>0.03</b>
• <b>Not disclosed</b>	692(75.4)	226(24.2)	<b>1.0</b>		<b>1.0</b>	
<b>Antiretroviral drug regimen</b>						
• <b>NNRTI based</b>	135866.2)	693(33.9)	<b>1.0</b>	<b>0.01</b>	<b>1.0</b>	<b>0.01</b>
• <b>PI Based</b>	664(76.0)	210(24.0)	<b>1.6(1.1 - 2.4)</b>		<b>1.3(1.2 - 2.1)</b>	
<b>Duration on HAART (month)</b>				<b>0.00</b>		0.06
• <b><math>&lt; 96</math></b>	1333(76.5)	410(23.5)	<b>1.5(1.1-2.1)</b>		1.4(0.9-2.4)	
• <b><math>\geq 96</math></b>	801(67.8)	381(32.2)	<b>1.0</b>	<b>0.01</b>	1.0	0.07
<b>Had opportunistic infection</b>	401(78.8)	108(21.2)	<b>1.6(1.1 – 2.4)</b>		1.4(0.8-1.7)	

NNRTI: Nucleoside reverse transcriptase inhibitors; PI: Protease inhibitor